Next, immunohistochemistry (IHC) showed that PLOD3 was upregulated in CRC tissues, as reflected by the increased H-scores obtained (Fig. 1B), which is consistent with the Clinical Proteomic Tumor Analysis Consortium (CPTAC) data (Fig. S1B). Here, PLOD3 is linked to neoplasm.